- Home
- WDAY vs ARGX Comparison
WDAY vs ARGX Comparison
Compare WDAY & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDAY | ARGX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7B | 52.6B |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WDAY | ARGX |
|---|---|---|
| Price | $204.48 | $853.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 19 |
| Target Price | $280.10 | ★ $971.89 |
| AVG Volume (30 Days) | ★ 2.5M | 271.1K |
| Earning Date | 11-25-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.37 | ★ 23.27 |
| Revenue | ★ $9,231,000,000.00 | $3,683,281,000.00 |
| Revenue This Year | $15.24 | $91.44 |
| Revenue Next Year | $12.32 | $36.90 |
| P/E Ratio | $90.46 | ★ $33.59 |
| Revenue Growth | 13.17 | ★ 92.98 |
| 52 Week Low | $205.33 | $510.06 |
| 52 Week High | $283.68 | $934.62 |
Technical Indicators
Market Signals| Indicator | WDAY | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 43.48 |
| Support Level | $213.63 | $835.02 |
| Resistance Level | $220.93 | $858.80 |
| Average True Range (ATR) | 4.48 | 13.81 |
| MACD | -0.60 | -2.96 |
| Stochastic Oscillator | 5.89 | 36.92 |
Price Performance
Historical ComparisonAbout WDAY Workday Inc.
Workday is a software company that offers human capital management, financial management, and business planning solutions for enterprises. Known for being a cloud-only software provider, Workday was founded in 2005 and is headquartered in Pleasanton, California.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.